Drug Falling Off Patent? Here’s 4 Ways Biocatalysis Can Soften the Landing

For some, Loss of Exclusivity (LoE) may be just a deadline on a calendar. But for us, it’s quite the strategic inflection point.

As key products approach the "patent cliff," pharmaceutical companies usually start facing a series of tough questions:

• • How resilient are our manufacturing costs?
  • Do we have freedom-to-operate (FTO) exposure?
  • Can we tighten our impurity control under sudden competitive pressure?

And while lifecycle management (LCM) usually focuses on new formulations or indications, process innovation is a lever that is frequently overlooked until the window for implementation starts to close. This oversight is exactly why biocatalysis presents the biggest potential for shifting from a 'nice-to-have' green chemistry niche to a core strategic tool.

In our experience, while we find that biocatalysis is most effective when treated as an initial strategy for development, it is equally powerful for assets already in production. When a process is already established, biocatalysis can protect and fortify your position as loss of exclusivity approaches.

Here are 4 ways biocatalysis can help pharma teams navigate the challenges of Patent Cliff 2.0:

1. Gain Process Leverage

When generics enter the market, the price drop is immediate. Even if an originator retains a solid market share, manufacturing costs (COGS) will be under a microscope.

In the many cases we've analyzed over the years as an enzyme discovery and engineering provider, integrating a biocatalytic step fundamentally changes the economic profile of an API.

By leveraging enzymatic selectivity, companies can often:

• • Reduce synthetic step count: Enzymes can consolidate multiple chemical transformations into a single step, simplifying routes and reducing cycle time.
  • Eliminate protecting groups: Enzymes selectively target specific functional groups, avoiding the need for protection and deprotection steps that increase cost, time, and waste.
  • Simplify downstream processing: Highly selective enzymatic reactions produce cleaner reaction mixtures, reducing purification complexity and minimizing costly separations.
  • Improve overall yield and carbon efficiency: By minimizing side reactions, enzymes convert a greater fraction of starting materials into the desired product, improving yield and lowering raw material costs.
  • Enable cascade reactions: Multiple enzymatic transformations can be combined into one-pot processes, eliminating intermediate isolation and reducing operational complexity.

Remember: Not every transformation may benefit from enzymatic integration, so feasibility assessments are recommended to check if a biocatalytic route is possible and the chances it has of materially improving your competitiveness.

2. IP and Freedom-to-Operate (FTO)

From a strategic standpoint, the adoption of biocatalysis offers two new ways to navigate the IP landscape:

Defensive Mapping

Computational exploration of the enzyme sequence space allows companies to identify multiple viable enzymatic variants early. As a consequence, this helps teams:

• • Carry out FTO analysis across different enzyme families
    
  • Assess potential overlap with existing biocatalytic patents
    
  • Strategically select sequences with lower infringement risk
    
  • Reduce the risk of committing to a candidate that later proves constrained

Secondary Positioning

Newly discovered and engineered enzymes lead to the introduction of structural differentiation at the sequence level. This allows for new process claims tied to specific engineered variants or based on documented technical improvements (e.g., activity, selectivity, stability), creating a fresh layer of technical protection around the manufacturing process.

3. Purity Control

Enzymatic transformations offer a level of precision that traditional chemistry struggles to match, leading to:

• • High stereochemical fidelity for chiral centers: By ensuring that only the desired enantiomer is produced from the start, we can virtually eliminate the risk of trace chiral impurities that are often nearly impossible to separate using traditional chemical means.
  • Reduced byproduct formation: Traditional high-energy reactions often trigger unwanted side-reactions. Because enzymes operate under mild conditions and with high substrate specificity, the resulting crude mixture is significantly cleaner, reducing the analytical burden required to characterize and clear complex impurity profiles.
  • Fewer metal contaminants: Many late-stage synthetic routes rely on palladium, platinum, or other transition metals which require rigorous (and expensive) scavenging protocols to meet strict regulatory limits. Switching to a biocatalyst removes these heavy metals from the equation, simplifying your elemental impurity risk assessment.
  • Simplified downstream purification: A cleaner reaction profile creates a waterfall effect on the rest of the process. When you have fewer byproducts and no metal catalysts to remove, the workup becomes faster and uses fewer resources, often allowing for crystallization-driven isolations rather than costly and slow preparative chromatography.

4. Faster Route Decisions

Traditionally, enzyme development has been known for being slow and uncertain. Identifying an enzyme capable of performing a new transformation often required extensive experimental screening, iterative engineering, and significant trial and error. Many projects encountered dead ends, with no measurable activity after months of effort. 

But advances in physics-based simulations now allow scientists to predict, with high accuracy, how likely it is that an enzyme can catalyze a specific chemical transformation. Instead of relying on blind screening, computational methods can evaluate thousands of enzymes in silico, identifying promising candidates and estimating the probability of success before entering the lab.

This enables something unprecedented: rapid, data-driven feasibility assessment. When evaluating a new target molecule, it is now possible to obtain a quantified risk profile within days, indicating how likely it is that an enzymatic solution exists. This allows process development teams to make informed route decisions early—before committing significant resources to longer, more complex synthetic strategies.

Even more importantly, computational design dramatically accelerates the path to experimental validation. Once promising candidates are identified, laboratory confirmation can often be achieved within weeks, delivering the first proof of concept that the transformation is viable.

Instead of evaluating biocatalysis late in development as an optimization step, it can now be assessed at the outset, when route selection decisions have the greatest impact on cost, scalability, and intellectual property.